NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Thanks Chiugray. This is my reasoned interpretation based on Advent’s MHRA licence, SEC filings, and the Eden patent.

Early filings listed 2 Grade B artisan suites and a planned Grade C lab but not the 3 active Grade C cleanrooms already licensed under MHRA MIA 54923 or the 2 Grade D rooms that support them. Bruce’s post helped confirm this:
🔗

Exactly. Correlates with this yearly magazine. So much nonsens spouted about this. They have C cleanrooms.

👍🏻 pic.twitter.com/xfpT0au7Fx

— 🇩🇰 The Danish Dude 🇬🇱 (@FlemmingBruce) October 6, 2025

Advent now has 3 Grade C rooms (Eden ready) + 2 more in the leased GMP facility, backed by 2 Grade D prep rooms—5 Grade C suites total.

At the 2024 ASM Linda Powers said each Grade C lab can make ~1–1.1 K patients/yr and full build-out ~15 K per yr. Eden wasn’t yet validated (Mar 31 2025 10-Q), so that number was conservative.

Eden’s patent describes a closed, automated DC-vaccine system using single-use cartridges swapped every 8 days, eliminating downtime and turning each unit into a continuously cycling bioreactor.

Cartridge logic
• Baseline per Grade C suite = 1–1.1 K patients/yr
• With Eden cycling (×2.7–3.0) = 2.7–3.3 K per suite
• 5 suites ˜ 13.5–16.5 K patients/yr
• + 2 Grade B suites (˜ 1–1.2 K total) ˜ 14.5–17.7 K combined

So the math behind 3 K per suite isn’t arbitrary—it follows Eden’s patent. The cartridge system cuts idle time, Grade C adds density, and Grade D staging keeps production constant. Even using the conservative baseline (5 × 1.1 K ˜ 5.5 K), the model still aligns with the ~15 K capacity Linda Powers outlined once Eden is fully validated.

All math and assumptions are my own based on public data.